Navigation Links
Study Aims At The Immune System In Patients With Lou Gehrig's Disease

Carolyn Shimek takes cholesterol-decreasing medications like millions of Americans. However she does not have high cholesterol like others//. This is since she is taking part in a different clinical study found only at the Methodist Neurological Institute (NI) to view the benefits of Lipitor on the immune system in patients with Lou Gehrig's disease, or amyotrophic lateral sclerosis (ALS).

Physicians at the Methodist NI's MDA/ALS Clinical Center diagnosed the 48-year-old Victoria, Texas resident in 2005. When she learned of this investigator-initiated research, Shimek knew she had to give it a chance.

‘I have a lot to live for - my family and friends,’ said Shimek, a wife, mother of three, and one of 12 siblings. ‘If participating in this study means it will help me or other ALS patients down the road then it's worth it.’

Dr. Ericka Simpson, co-director of Methodist's ALS Clinic, is the primary investigator who oversees this double-blind study in which patients will be randomly assigned to receive the drug or a placebo. Simpson believes the immune system plays an important role in how ALS affects patients.

‘Lipitor has been shown to regulate immune responses that may provide protection in diseases of the central nervous system. Our goal is to determine whether Lipitor has the ability to improve the course of disease progression and quality of life for our ALS patients,’ said Simpson.

Currently, the only FDA-approved drug therapy for ALS is Rilutek. The drug has been shown to modestly improve patient survival, but has no measurable affect on function or the rate of disease progression. ALS is a progressive neurodegenerative disease characterized by degeneration of the upper and lower motor neurons in the brain and spinal cord which stimulate skeletal muscle movement. As more motor neurons die, muscle weakness gets progressively worse. An estimated 30,000 people throughout the U.S. have ALS, and 8,000 new cas es are diagnosed each year.

Source: Neswise
'"/>




Related medicine news :

1. Tomato Sauce reduces Cancer Risk- Study
2. Study on obesity and heart failure
3. National Lung Study in the process
4. Study casts doubt on keyboard ills
5. Study reveals how stress can make you sick
6. Study reveals how stress can make you sick
7. Study supports vegetable diet
8. Study to look at early surgery to treat epilepsy
9. Its Never Too Late to Stop Smoking,Study Finds
10. New Technique to Study Infants Brain.
11. Groundbreaking Study Gives Hope For Patients With Kidney Cancer
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/21/2017)... Va. (PRWEB) , ... September 21, 2017 , ... ... with a different approach to addiction recovery at a time when Virginia faces ... deaths resulting from drug overdose, a staggering increase of 38 percent from 2015, ...
(Date:9/21/2017)... ... September 21, 2017 , ... ... the acquisition of Isle at Kingwood Assisted Living and Memory Care located at ... retirement community with 55 assisted living apartments, 43 memory care apartments and 23 ...
(Date:9/21/2017)... ... September 21, 2017 , ... In ... and Clark College Emeritus Professor of Education Gregory A. Smith examines student privacy ... Asleep at the Switch: Schoolhouse Commercialism, Privacy, and the Failure of Policymaking . ...
(Date:9/20/2017)... CHARLOTTE, NC (PRWEB) , ... September 20, 2017 ... ... for Transformation and Centers of Excellence (CoE) with the latest Artificial Intelligence (AI) ... newly designed presence offers quick and easy access to essential information that offers ...
(Date:9/20/2017)... , ... September 20, 2017 , ... ... one of the Best Places to Work in the Research Triangle for 2017. ... Once nominated, a company had to meet a threshold in employee participation--a percentage ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)... Ind. , Sept. 7, 2017  Zimmer Biomet ... in musculoskeletal healthcare, today announced that it will be ... Global Healthcare Conference at the Grand Hyatt hotel in ... 11, 2017 at 11:40 a.m. Eastern Time. ... via Zimmer Biomet,s Investor Relations website at http://investor.zimmerbiomet.com ...
(Date:9/6/2017)... Sept. 6, 2017 NeuroRx, a clinical stage biopharma ... and Behavior (ASIB), has been granted Fast Track status by ... of NRX-100 (ketamine HCl) followed by NRX-101 (D-cycloserine + lurasidone). ... trial of this sequential therapy targeting patients who are admitted ... ...
(Date:9/5/2017)... LONDON , Sept. 5, 2017  Just 18 ... Valid Insight is pleased to announce the appointment of ... Tammy Wynne , Dominic Jones-Phillips and ... from industry. ... a team of market access writers. She has over ...
Breaking Medicine Technology: